Can Survodutide be used for fatty liver or MASH?

Yes, survodutide is currently being studied as a potential treatment for metabolic-associated steatohepatitis (MASH), a severe form of fatty liver disease, and liver scarring (fibrosis), in adults. So far, survodutide, a glucagon/GLP-1 receptor dual agonist, has shown the ability to improve MASH, reduce liver fat, and even reverse liver fibrosis in some patients.

In phase II trials, most people in the survodutide group (83%) saw a significant MASH reduction, while only 18.2% of those on a placebo achieved it. Survodutide was also better than a placebo in reducing liver fat content and liver scarring. All survodutide doses were generally safe and well tolerated, without any unexpected tolerability or safety issues.
Survodutide is currently in two Phase III clinical trials looking at its safety and efficacy in the treatment of adults living with MASH and fibrosis (scarring).